This CME/CNE program will highlight recent advances in the treatment and management of multiple sclerosis (MS) as presented at the 70th Annual American Academy of Neurology Meeting held in Los Angeles, California. The four expert faculty, led by Dr. Fred Lublin, will review the pathophysiology of MS as well as the mechanisms of action of current therapies. The role of biomarkers in disease progression and response to therapy will be explored. Clinical trial data, particularly that of approved/emerging therapeutics and supportive care, will be analyzed and clinical relevance debated. Upon completion of this educational activity, learners will gain insight into how to better provide personalized, comprehensive care for patients with MS.
Neurologists, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with multiple sclerosis
- Identify the pathophysiology of multiple sclerosis, along with the mechanisms of action of newer therapeutics
- Analyze clinical trial data of current and emerging therapeutics for the treatment of MS, as presented at AAN 2018
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Fred D. Lublin, MD (Course Chair)||Consultant/Advisor: AbbVie, Inc.; Acorda Therapeutics; Actelion Pharmaceuticals US, Inc.; Apitope; Atara Biotherapeutics; Bayer HealthCare Pharmaceuticals LLC; Biogen; Celgene Corporation; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd.; Forward Pharma; Genentech, Inc.; Innate Immunotherapeutics Limited; Mapi-Pharma Ltd.; MedDay; MedImmune; Novartis Pharmaceuticals Corporation; Polpharma; Receptos, Inc.; Regeneron; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; Toyoma Chemical Co., Ltd.Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.; Transparency Life Sciences|
|Suhayl Dhib-Jalbut, MD||Consultant/Advisor: Celgene CorporationGrant/Research Support: Biogen; Teva Pharmaceutical Industries Ltd.|
|Michelle Fabian, MD||Speaker’s Bureau: Biogen|
|Thomas P. Leist, MD, PhD||Consultant/Advisor: Actelion Pharmaceuticals US, Inc.; Biogen; EMD Serono, Inc.; Janssen Global Services, LLC;Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.Grant/Research Support: Biogen; Novartis Pharmaceuticals Corporation; MedDaySpeaker’s Bureau: Biogen; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski; and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.50 CNE contact hours (1.50 CNE pharmacotherapeutic contact hours).
This activity has been supported by independent educational grants from Biogen and Celgene Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Biogen and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].